[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"survivor-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:survivor-patients":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":4},"100636885","helping-young-people-with-testicular-cancer-using-virtual-and-extended-reality-100636885",false,"NCT07571499","Helping Young People With Testicular Cancer Using Virtual and Extended Reality","Addressing TesticulaR cANcer Unmet Supportive CarE NeeDs in Adolescents and Young Adults Using eXtended Reality","TRANSCEND-XR","Inclusion Criteria:\n\n1. Any person assigned male at birth who is diagnosed with stage I-III TC (germ cell tumour of the testicles).\n2. Aged between 15 and 39 years at the time of study inclusion.\n3. Completed curative treatment comprising of at least one standard treatment modality (surgery, chemotherapy and\u002For radiotherapy) for treatment of their cancer. A maximum of 9 months from the end of curative treatment will be allowed.\n4. Permitted treatment modalities:\n\n   * Localised disease: orchiectomy with or without chemotherapy and\u002For radiotherapy.\n   * Metastatic disease: orchiectomy and chemotherapy or radiotherapy or retroperitoneal surgery, or a combination of aforementioned treatments. First-line treatment only allowed.\n5. Willing and able to provide a valid and signed informed consent and\u002For assent, as appropriate.\n6. ECOG performance status 0-2.\n7. Patients accept to use personal smartphone\n8. Patients able to read and understand the local language\n\nExclusion Criteria:\n\n1. Non-testicular germ cell tumours (e.g., mediastinal primary or retroperitoneal primary tumours).\n2. Non-germ cell TC.\n3. Previous chemotherapy, radiotherapy, or surgery for TC other than that allowed in IC 4.\n4. History of contralateral TC.\n5. Any illness that would prevent the AYA TC survivor from giving a valid and signed informed consent, as assessed by the investigator.\n6. Any illness that might be exacerbated by the use of an XR digital tool, as assessed by the investigator, including history of severe motion sickness, brain lesions and epilepsy.\n7. Uncontrolled medical condition such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease (including but not limited to grade 2 or higher cardiac failure, arrythmia, unstable angina, history of myocardial infract in the 6 months which, in the opinion of the treating physician, would influence the assessment of long-term side effect of TC treatment.\n8. AYA TC survivors with a \"currently active\" second malignancy other than non-melanoma skin cancers, superficial non-invasive (pTa or pTis) TCC of the bladder, or intratubular germ cell neoplasia. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for ≥ 3 years.\n9. Chemotherapy or radiotherapy for malignant disease other than TC within the past 3 years.","MALE","15 Years","39 Years",{"count":21,"type":22},245,"ESTIMATED","INTERVENTIONAL",[25],"NA","TRANSCEND-XR is a European research project designed to better support adolescents and young adults who have been cured of testicular cancer. Even after treatment has ended, many young people continue to face physical, psychological, or social difficulties that are often poorly understood and insufficiently addressed.\n\nThe project aims to develop an innovative digital tool using extended reality (XR) to help these young people better understand the potential long-term effects of the disease and its treatments, recognize signs that require medical attention, and become more active participants in their own health follow-up.\n\nTRANSCEND-XR first includes a pilot phase to test feasibility and improve the tool, followed by a larger clinical study comparing its use with usual medical follow-up. Researchers will assess, in particular, its impact on patients' knowledge, quality of life, and ability to seek help.\n\nThe ultimate goal is to sustainably improve information, autonomy, and well-being among young survivors of testicular cancer through a digital approach tailored to their needs and daily practices.",[28,29,30,31],"Testicular Cancer","Testis Cancer","AYA Cancer Survivors","Survivor Patients",[33,34,35,36,37,38,39,40,41,42,43,44,45],"Testicular cancer survivors","Adolescents and young adults (AYA)","Survivorship care","Supportive care needs","Late effects of cancer treatment","Post-cancer follow-up","Quality of life","Patient education","Extended reality (XR)","Virtual reality in healthcare","Digital health intervention","Immersive digital tools","Long-term cancer effects","NOT_YET_RECRUITING","2026-04-30",{"date":49,"type":50},"2026-05-06","ACTUAL",{"date":52,"type":22},"2027-01-04",{"date":54,"type":22},"2029-06-30",{"name":56,"class":57},"Gustave Roussy, Cancer Campus, Grand Paris","OTHER",{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":65,"minAge":66,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100627378","phase-1-a-study-testing-topical-pain-relieving-herbal-plasters-in-people-who-are-using-opioids-for-their-pain-100627378","NCT07447856","A Study Testing Topical Pain-Relieving Herbal Plasters in People Who Are Using Opioids for Their Pain","Integrating Topical Herbal Plasters to Enhance Pain Management and Reduce Opioid Use in Cancer Patients (EASE)","Inclusion Criteria:\n\n* English speaking with age ≥ 18 years or older\n* A diagnosis of cancer with no restrictions placed on type of cancer or stage. Eligibility criteria will not be restricted to MSK confirmed biopsy\u002Fdiagnosis. Outside institution's testing is sufficient.\n* Ambulatory (Karnofsky Performance Status of ≥ 60)\n* Having one of three types of pain (e.g., musculoskeletal pain, bone metastasis pain, and visceral\u002Fabdominal pain) and the worst pain area can be covered by one patch of topical herbal plaster\n* Worst pain score (measured by the 0-10 numeric pain rating scale) 4 or above in the preceding week\n* Current use of short-term oral opioids (i.e. oxycodone, morphine immediate release, or hydromorphone) for pain management.\n* Willingness to adhere to and understanding of all study-related procedures, including randomization to one of the two possible study arms\n* Able to understand informed consent and provide signed informed consent form\n\nExclusion Criteria:\n\n* Patients are unwilling to reduce opioid use if their pain reduces\n* Patients have generalized musculoskeletal pain such as fibromyalgia as primary source of pain\n* Patients with clinician confirmed significant skin disorders such as severe eczema, psoriasis, severe xerosis, chronic dermatitis, or adhesive allergy.\n* Patients with open wounds, infections, skin trauma at skin overlying area of pain\n* Patients with documented history of skin sensitivity to adhesive or allergic reaction to other patches or topical analgesics\n* Patients with documented skin allergic reaction to plants or herbs\n* Patients who are unwilling to hold their current localized topical pain treatment (such as lidocaine patch) for the most severe pain site.\n* Patients who undergo initiation or change in pain management strategies within 1 week prior to enrollment, including oral analgesics (e.g., opioids, NSAIDs), medications that can significantly reduce pain (e.g., bisphosphonates, denosumab), or interventional procedures (e.g., nerve blocks, palliative radiation).\n* Patients who are planned to undergo initiation or change of the above pain management strategies in the 2 weeks following enrollment.\n* Patients who undergo initiation or change in standard cancer treatments (surgery, radiation, chemotherapy, hormonal therapy, immunotherapy, or targeted therapy) 1 week prior to enrollment.\n* Patients who are planned to undergo initiation or change of active cancer treatments (surgery, radiation, chemotherapy, hormonal therapy, immunotherapy, or targeted therapy) in the 2 weeks following enrollment.","ALL","18 Years",{"count":68,"type":22},150,[70],"PHASE1","The are doing this study to find out whether using topical (on the skin) herbal plasters, Tibetree pain- relieving plasters (PRPs), can be an effective addition to standard opioid therapy for pain management. The researchers will look at whether the Tibetree PRPs are a practical (feasible) and effective way of managing localized pain (pain that is limited to a certain area) in people who are currently taking opioids. Participants in this study will have cancer or have had it in the past.",[73,31,74],"Cancer Patients","Cancer Pain",[76,77,78,79,80,81],"Tibetree","Tibetree Pain-Relieving","Cancer","Pain","Cancer survivor","25-376","RECRUITING","2026-02-25",{"date":85,"type":50},"2026-03-04",{"date":87,"type":50},"2026-02-23",{"date":89,"type":22},"2028-02",{"name":91,"class":57},"Memorial Sloan Kettering Cancer Center",7]